Adage Capital Partners
MREO

Adage Capital Partners’s Mereo BioPharma MREO Stock Holding History

Adage Capital Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,700,756
Closed -$3.83M – 913
2025
Q1 		$3.83M Sell
1,700,756
-7,014,257
-80% -$19.8M 0.01% 726
2024
Q4 		$30.5M Sell
8,715,013
-1,000,000
-10% -$3.93M 0.05% 322
2024
Q3 		$39.9M Sell
9,715,013
-2,076,297
-18% -$8.59M 0.07% 279
2024
Q2 		$42.4M Buy
11,791,310
+2,462,571
+26% +$7.98M 0.08% 243
2024
Q1 		$30.8M Buy
9,328,739
+6,678,739
+252% +$22.6M 0.06% 347
2023
Q4 		$6.12M Buy
2,650,000
+1,850,000
+231% +$3.54M 0.01% 662
2023
Q3 		$1.03M Buy
+800,000
New +$1.06M ﹤0.01% 763
2022
Q1 		– Sell
-1,000,000
Closed -$1.6M – 1113
2021
Q4 		$1.6M Hold
1,000,000
– – ﹤0.01% 879
2021
Q3 		$2.42M Buy
+1,000,000
New +$2.65M ﹤0.01% 888

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners's MREO Position: Q2 2025 in Review

Adage Capital Partners sold out of Mereo BioPharma (MREO) in Q2 2025, closing a stake of 1,700,756 shares — an estimated $3.83M sold.

Adage Capital Partners first reported a position in MREO in Q3 2021 and held it in 9 quarters. The position peaked at $42.4M in Q2 2024. 86 funds tracked by Wall St. Rank hold MREO as of Q2 2025.

  • Adage Capital Partners reported no remaining Mereo BioPharma position as of Q2 2025 after selling out during the quarter.
  • Adage Capital Partners sold 1,700,756 Mereo BioPharma shares in Q2 2025, an estimated $3.83M.
  • Adage Capital Partners first reported a position in Mereo BioPharma in Q3 2021 and held it in 9 quarters.
  • Adage Capital Partners's Mereo BioPharma position peaked at $42.4M in Q2 2024.
  • 86 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2025.

Based on Adage Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.